Drug Trial Radar · NCT07386002
The GLIOMAX Study: MT027 Allogeneic CAR-T for Recurrent Glioma
Last checked: Nov 20, 2026Latest source record: Oct 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
40
Planned (sponsor's estimate)
Start
Nov 30, 2026
Primary completion
Dec 13, 2028
Study completion Jul 31, 2029
Sponsor
- Lead sponsor
- T-MAXIMUM Pharmaceutical IncIndustry
- Sponsor type
- Industry
- Collaborators
- Virginia Contract Research Organization Co., Ltd.
- First posted
- Feb 4, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase II trial to evaluate the safety, tolerability, efficacy, and PK/ pharmacodynamic profiles of MT027 injected via ICV in participants with recurrent or progressive IDH-wildtype glioblastoma (WHO 2021 CNS Grade 4), who have previously received standard of care (SOC) therapy. Each participant will undergo screening, treatment (receiving MT027 at a dose of 3×10\^7 cells), safety follow-up, and long-term follow-up periods. MT027 will be given via ICV injection on Day 1 \& Day 15 of the first 28-day cycle. If the participant does not experience any unacceptable toxicities and disease progress in the first cycle, additional treatment may be continued bi-weekly in a 28-day cycle (Days 1 \& Day 15 of the 28-day cycle) until intolerable toxicity, disease progression, withdrawal from the study, or death, whichever comes first. After the last dose, there will be a safety follow-up period lasting for 1 year and then a long-term follow-up up to 15 years.
Conditions
- Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype
Interventions
Intracerebroventricular injection of MT027 UCAR-T Cell targeting B7H3Biological
MT027 will be injected intracerebroventricularly at a dose of 3×10\^7 cells on Day 1 \& Day 15 of each 28-day treatment cycle.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence rate of Dose-limiting toxicity (DLT)Time frame: From the first dose to 2 weeks after the second dose
- 12-month overall survival (OS) rateTime frame: From the first dose to 12 months after the treatment
Locations
4 sites in 2 countries. Site status is shown where the registry gives one.
The Johns Hopkins Sidney Kimmel Cancer Center
Baltimore, Maryland
Hualien Tzu Chi Hospital
Hualien City, Taiwan
Chang Gung Memorial Hospital, Kaohsiung
Kaohsiung City, Taiwan
Chang Gung Memorial Hospital, Linkou
Taoyuan, Taiwan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.